National Vision (EYE) Competitors

Soleno Therapeutics (NASDAQ:SLNO) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Does the MarketBeat Community favor SLNO or EYE?

Soleno Therapeutics received 66 more outperform votes than National Vision when rated by MarketBeat users. Likewise, 72.56% of users gave Soleno Therapeutics an outperform vote while only 64.80% of users gave National Vision an outperform vote.

Company	Underperform	Outperform
Soleno Therapeutics	Outperform Votes 320 72.56%	Underperform Votes 121 27.44%
National Vision	Outperform Votes 254 64.80%	Underperform Votes 138 35.20%

Is SLNO or EYE more profitable?

Soleno Therapeutics has a net margin of 0.00% compared to National Vision's net margin of -0.81%. National Vision's return on equity of 3.52% beat Soleno Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	N/A	-61.99%	-55.21%
National Vision	-0.81%	3.52%	1.39%

Which has better earnings and valuation, SLNO or EYE?

Soleno Therapeutics has higher earnings, but lower revenue than National Vision. National Vision is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	N/A	N/A	-$38.99M	-$4.26	-16.49
National Vision	$1.82B	0.50	-$65.90M	-$0.36	-32.39

Which has more volatility & risk, SLNO or EYE?

Soleno Therapeutics has a beta of -2.29, meaning that its stock price is 329% less volatile than the S&P 500. Comparatively, National Vision has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Do analysts recommend SLNO or EYE?

Soleno Therapeutics presently has a consensus price target of $99.63, suggesting a potential upside of 41.81%. National Vision has a consensus price target of $14.00, suggesting a potential upside of 20.07%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Soleno Therapeutics is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22
National Vision	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Do institutionals and insiders hold more shares of SLNO or EYE?

97.4% of Soleno Therapeutics shares are owned by institutional investors. 12.3% of Soleno Therapeutics shares are owned by insiders. Comparatively, 2.3% of National Vision shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media refer more to SLNO or EYE?

In the previous week, Soleno Therapeutics had 6 more articles in the media than National Vision. MarketBeat recorded 13 mentions for Soleno Therapeutics and 7 mentions for National Vision. National Vision's average media sentiment score of 1.37 beat Soleno Therapeutics' score of 1.07 indicating that National Vision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soleno Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Vision	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Soleno Therapeutics beats National Vision on 12 of the 18 factors compared between the two stocks.